Problem of immortal time bias in cohort studies: Example using statins for preventing progression of diabetes

BMJ (Online)

Volumn 340, Issue 7752, 2010, Pages 907-911

  Lévesque, Linda E ^a,b,c   Hanley, James A ^a,d   Kezouh, Abbas ^d   Suissa, Samy ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c Kingston   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; EPIDEMIOLOGY; FOLLOW UP; HUMAN; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TIME; TREATMENT OUTCOME; VALIDATION PROCESS;

BIAS (EPIDEMIOLOGY); COHORT STUDIES; DIABETES MELLITUS; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TIME FACTORS;

EID: 77951579430     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b5087     Document Type: Article

References (31)

1. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38. (Pubitemid 46041751)
2. Lévesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142:481-489 (Pubitemid 40490913)
3. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366.
4. Lévesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 2006;174:1563-1569 (Pubitemid 43829511)
5. Strom BL. Study designs available for pharmacoepidemiology studies. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. John Wiley, 2005:17-28.
6. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ. Users' guides to the medical literature. IX. A method for grading health care recommendations. JAMA 1995;274:1800-1804
7. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007;16:241-249 (Pubitemid 46431687)
8. Rothman KJ, Greenland S. Cohort studies. In: Rothman KJ, Greenland S, eds. Modern epidemiology. 2nd ed. Lippincott-Raven, 1998: 79-91.
9. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-584 (Pubitemid 32801660)
10. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary non-adherence after acute myocardial infarction. Circulation 2008;117:1028-1036
11. Sheehy O, LeLorier J, Rinfret S. Restrictive access to clopidogrel and mortality following coronary stent implantation. CMAJ 2008;178:413-420 (Pubitemid 351303283)
12. Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007;61:300-306
13. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007;357:1373-1381
14. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11 942 elderly patients with heart failure. Am J Med 2002;113:650-656
15. Yee A, Majumdar SR, Simpson SH, McAlister FA, Tsuyuki RT, Johnson JA. Statin use in type 2 diabetes mellitus is associated with a delay in starting insulin. Diabet Med 2004;21:962-967
16. Downey W, Stang M, Beck P, Osei W, Nichol JL. Health services databases in Saskatchewan. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. John Wiley, 2005:295-310.
17. Standards of medical care in diabetes. Diabetes Care 2004;27(suppl 1):S15-35.
18. Kleinbaum DG, Kupper LL, Muller KE, Nizam A, eds. Poisson regression analysis. In: Applied regression analysis and other multivariable methods. 3rd ed. Duxbury Press, 1998:687-709.
19. Cox DR. Regression models and life-tables. J R Stat Soc Ser B 1972;34:187-220.
20. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
21. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-864
22. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2008;167:492-499
23. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003;168:49-53.
24. Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004;23:391-395
25. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002;20:819-825
26. Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 2005;162:1016-1023
27. Liddell FDK, McDonald JC, Thomas DC. Methods of cohort analysis: appraisal by application to asbestos mining. J R Stat Soc Ser A 1977;140:469-491
28. Breslow NE, Day NE, eds. Fitting models to continuous data. Statistical methods in cancer research. Vol.2. The design and analysis of cohort studies. IARC Scientific Publications, 1987:178-229.
29. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. John Wiley, 2005:811-829
30. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-467
31. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004;19:638-645